Morschhauser, F <br/><br/>
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2012 
 - 2687-2695 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mds202  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Lymphoma, Follicular--drug therapy<br/>Middle Aged<br/>Neoplasm, Residual<br/>Polymerase Chain Reaction<br/>Prospective Studies<br/>Rituximab<br/>Young Adult